1 Urinary Volatile Organic Compound Metabolites are Associated with High Blood

2 Pressure Among Non-smoking Participants in the National Health and Nutrition

3 Examination Survey (2011-2018)

- 4
- 5 Authors:
- 6 Katlyn E. McGraw^{1*} PhD, Arce Domingo-Relloso¹ PhD, Daniel W. Riggs² PhD, Danielle
- 7 N. Medgyesi¹ MS, Raghavee Neupane³ MPH, Jeanette A. Stingone⁴ PhD, Tiffany R.
- 8 Sanchez¹ PhD
- 9
- 10 Affiliations:
- ¹Columbia University Mailman School of Public Health
- 12 Department of Environmental Health Science
- 13 722 W 168th St, New York, NY 10032
- 14
- ¹⁵ ²Christina Lee Browne Envirome Institute
- 16 University of Louisville
- 17 322 W Muhammad Ali Blvd, Louisville, KY 40202
- 18
- ¹⁹ ³Dr. Kiran C. Patel College of Osteopathic Medicine
- 20 Nova Southeastern University
- 21 3200 S University Dr, Fort Lauderdale, FL 33328
- 22
- ⁴ Columbia University Mailman School of Public Health
- 24 Department of Epidemiology
- 25 722 W 168th St, New York, NY 10032
- 26
- 20
- 28 * Correspondence:
- 29 Katlyn E. McGraw, PhD
- 30 Columbia University Mailman School of Public Health
- 31 Department of Environmental Health Science
- 32 722 W 168th St, New York, NY 10032
- 33 Tel: 212-305-4596
- 34 Email: <u>kem2240@cumc.columbia.edu</u>
- 35
- 36
- 37 **Short title:** VOC Exposure and Blood Pressure NHANES 2011-2018
- 38
- 39 Word count: 7,851
- 40
- 41 Keywords:
- 42 Volatile organic compounds, blood pressure, mixtures, acrolein, butadiene
- 43

44 **ABSTRACT**

Background: Volatile organic compounds (VOCs) are ubiquitous environmental 45 pollutants. Exposure to VOCs is associated with cardiovascular disease (CVD) risk 46 factors, including elevated blood pressure (BP) in susceptible populations. However, 47 research in the general population, particularly among non-smoking adults, is limited. 48 49 We hypothesized that higher VOC exposure is associated with higher BP and hypertension, among non-smokers. 50 51 Methods: We included four cycles of data (2011-2018) of non-smoking adults (n=4,430) 52 from the National Health and Nutrition Examination Survey (NHANES). Urinary VOC 53 metabolites were measured by ultra-performance liquid chromatography-mass 54 spectrometry, adjusted for urine dilution, and log-transformed. We estimated mean 55

56 differences in BP using linear models and prevalence ratio of stage 2 hypertension

using modified Poisson models with robust standard errors. Models were adjusted for

age, sex, race and ethnicity, education, body mass index, estimated glomerular filtration

60

59

rate and NHANES cycle.

<u>Results:</u> Participants were 54% female, with a median age of 48 years, 32.3% had
hypertension, and 7.9% had diabetes. The mean differences (95% Cl) in systolic BP
were 1.61 (0.07, 3.15) and 2.46 (1.01, 3.92) mmHg when comparing the highest to
lowest quartile of urinary acrolein (CEMA) and 1,3-butadiene (DHBMA) metabolites.
The prevalence ratios (PR) for hypertension were 1.06 (1.02, 1.09) and 1.05 (1.01,

- 1.09) when comparing the highest to lowest quartiles of urinary acrolein (CEMA) and
- 1,3-butadiene (DHBMA), respectively.
- 68
- 69 <u>Conclusions:</u> Exposure to VOCs may be relevant yet understudied environmental
- contributors to CVD risk in the non-smoking, US population.

71 NON-STANDARD ABBREVIATIONS AND ACRONYMS

- 72 3HPMA N-Acetyl-S-(3-hydroxypropyl)-L-cysteine
- 73 BMI Body mass index
- 74 BKMR Bayesian Kernel Machine Regression
- 75 BP Blood pressure
- 76 CEMA N-Acetyl-S-(2-carboxyethyl)-L-cysteine
- 77 CI Confidence intervals
- 78 CVD Cardiovascular disease
- 79 DBP Diastolic blood pressure
- 80 DHBMA N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine
- 81 eGFR Estimated glomerular filtration
- 82 HDL High density lipoprotein cholesterol
- 83 HPMMA N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine
- 84 MA Mandelic acid
- 85 MHBMA3 N-Acetyl-S-(4-hydroxy-2-butenyl)-L-cysteine
- 86 MU t,t-Muconic Acid
- 87 NHANES National Health and Nutrition Examination Survey
- 88 PGA Phenylglyoxylic acid

- 89 PIPs Posterior inclusion probabilities
- 90 PMA N-Acetyl-S-(phenyl)-L-cysteine
- 91 SBP Systolic blood pressure
- 92 VOCs Volatile organic compounds
- 93

94 INTRODUCTION

Volatile organic compounds (VOCs) are an under regulated class of chemicals 95 characterized by low molecular weight and high vapor pressure, properties which lead 96 to rapid vaporization in ambient air.¹⁻⁴ Ambient VOCs are critical in the formation of 97 harmful secondary air pollutants such as ozone and PM_{2.5}.^{5, 6} However, VOCs emitted 98 99 directly from sources are just as harmful and include tobacco smoke, vehicle exhaust, industrial solvents, manufacture of consumer goods, and oil and gas refining.^{7, 8} Indoor, 100 VOC levels can be up to ten times higher than ambient VOC levels.⁸ Additionally, some 101 102 VOCs are produced endogenously through processes like lipid peroxidation, glycation, and amino acid oxidation.⁹⁻¹¹ Therefore, VOCs are ubiquitous environmental 103 104 exposures.

105

106 Urinary biomarkers of VOC exposure provide proximal, personal-level assessments of

all routes of exposure to VOCs, including ambient, indoor, and endogenous sources.

108 VOC metabolites from human biomonitoring have been associated with physician-

diagnosed cardiovascular disease (CVD),¹² metabolic syndrome,¹³ CVD risk factors,¹⁴⁻¹⁷

and ischemic heart disease mortality,¹⁸ particularly for acrolein, benzene, 1,3-butadiene,

111 crotonaldehyde, and styrene. However, these studies identified associations in small,

geographically homogenous cohorts, and in CVD-susceptible populations, including
individuals who smoke. The relation between VOC biomarkers and blood pressure
among non-smoking adults has not yet been elucidated in a large, representative
sample of the U.S. population, such as the National Health and Nutrition Examination
Survey (NHANES).

117

In this study, we evaluated the association between participants' VOC metabolite levels

in urine with measured blood pressure (BP) levels and hypertension defined as systolic

BP \geq 140 mmHg, diastolic BP \geq 90 mmHg, or self-reported use of BP medications¹⁹ using

data from a representative sample of the non-smoking U.S. adult population

participating in NHANES from 2011-2018. We hypothesized that exposure to VOCs,

specifically urinary metabolites of acrolein, benzene, 1,3-butadiene, crotonaldehyde,

and styrene, would be associated with higher BP levels and prevalence of hypertension.

Additionally, we conducted an exploratory assessment of all urinary VOC metabolites

measured in NHANES and mixtures of urinary VOC metabolites.

127 **METHODS**

128 Study Population

Led by the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention, NHANES is a series of continuous surveys designed to assess the health and nutritional status of adults and children in the U.S. NHANES is designed as a multiyear, stratified, clustered four-stage sample of noninstitutionalized civilians with fixed sample-size targets for sampling domains defined by age, sex, race and ethnicity, and socioeconomic status, with data released in 2-year cycles. Participants gave informed consent of the survey process and their rights as a participant, and the
survey was approved by the NCHS Review Board.²⁰ Questionnaires were administered
in-home followed by standardized health examinations in specially equipped mobile
examination centers. Deidentified and detailed health datasets are publicly available on
the NHANES website.²¹ We combined NHANES data from four cycles (2011-2018) to
create a larger and more geographically diverse sample, including all cycles with
available data on BP and urinary VOC metabolites.

142

143 Exclusion Criteria

Of the 39,156 NHANES participants from 2011-2018 combined, 23,825 were 18 years 144 of age and older. We focused on adults because blood pressure varies in childhood and 145 adolescence. There were 7,626 participants with measured urinary VOC metabolites 146 and BP examination data because 1/3 subsample at each cycle are analyzed for 147 environmental chemicals. Because tobacco smoke is a primary source of VOC 148 exposure, self-reported cigarette smoking, and serum cotinine data were used to 149 150 determine smoking status. We excluded 1,405 individuals who reported currently smoking cigarettes, an additional 451 individuals with serum cotinine levels >10 μ g/L, 151 reflecting recent nicotine exposure, and 480 missing self-reported cigarette smoking 152 status or cotinine data, for a final sample of 5,290 non-smoking participants. We further 153 excluded an additional 860 participants with missing data, including 492 missing priority 154 urinary VOCs, 172 missing systolic blood pressure (SBP), 11 missing diastolic blood 155 pressure (DBP), 81 missing urine creatinine, 42 missing BMI, 35 missing diabetes 156 status, 21 missing estimated glomerular filtration rate (eGFR), 3 missing triglycerides 157

(TG), 2 missing high density lipoproteins (HDL), and 1 missing education, for a total of
4,430 participants included in our analysis (Figure S1).

160

161 Urinary VOC Metabolites

162 Urine specimens were collected at mobile examination centers, frozen at -20°C, and

shipped to the Division of Environmental Health Laboratory Sciences, National Center

164 for Environmental Health for analysis.²² Ultra-performance liquid chromatography

165 coupled with electrospray tandem mass spectrometry was used to measure 35 VOC

metabolites of 20 parent compounds in urine in nanograms per milliliter (ng/mL).²³

167

168 We report results for 5 hypothesized, priority parent VOCs and their 9 associated

169 urinary metabolites: acrolein (CEMA – N-Acetyl-S-(2-carboxyethyl)-L-cysteine

and 3HPMA – N-Acetyl-S-(3-hydroxypropyl)-L-cysteine), benzene (MU – t,t-Muconic

171 Acid and PMA – N-Acetyl-S-(phenyl)-L-cysteine), 1,3-butadiene (DHBMA – N-Acetyl-S-

172 (3,4-dihydroxybutyl)-L-cysteine and MHBMA3 – N-Acetyl-S-(4-hydroxy-2-butenyl)-L-

173 cysteine), crotonaldehyde (HPMMA – N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-

174 cysteine), and styrene (PGA – N-Acetyl-S-(phenyl)-L-cysteine and MA – Mandelic

acid). PGA and MA are metabolites of ethylbenzene and styrene. See Table S1 for all

parent compounds, long and short metabolite names, NHANES cycle availability, and

limits of detection (LOD). Values below the LOD were imputed with the LOD/ $\sqrt{2}$.

Although the benzene metabolite, MU, was only available for one cycle (2017-2018,

n=1,046), we included MU in primary analyses for comparison to the other benzene

metabolite available at the other three cycles, PMA (2011-2016, n=3,207). To correct for

urine dilution, we divided all urinary VOC metabolites by urine creatinine and reported 181 levels as nanogram of VOC metabolite per milligrams of creatinine (ng/mg). 182 183 Blood Pressure and Hypertension 184 185 BP measurements were collected at mobile examination centers using a 186 187 sphygmomanometer and appropriately sized cuff for the participant's arm circumference. Three BP readings were collected after five minutes of seated rest. A 188 fourth measurement was collected if a measurement was interrupted or incomplete. All 189 190 recorded measurements of SBP and DBP were averaged and used as continuous outcome variables. 191 192 For hypertension, our primary endpoint was defined by having either a mean SBP ≥140 193 mmHg, a mean DBP ≥90 mmHg, or self-reported use of BP medications , also known 194 as stage 2 hypertension.¹⁹ We also conducted sensitivity analyses using two alternate 195 definitions: 1) stage 1 hypertension, where participants were hypertensive if mean SBP 196 197 ≥130 mmHg, mean DBP ≥80 mmHg, or were taking BP medications, and 2) if individuals self-reported physician-diagnosed hypertension. 198 199 Covariates 200 201 Age, sex, race and ethnicity, education, and household income were acquired from selfreported questionnaires. Race and ethnicity were classified as Mexican American, 202

203

Other Hispanic, Non-Hispanic White, Non-Hispanic Black, Non-Hispanic Asian, and

204 Other Races, including multiple races. We reclassified education as less than a high

school education, a high school education or GED equivalent, some college, or 205 bachelor's degree or more. Household income categories were reduced to \$0-\$24,999, 206 \$25,000-\$54,999, \$55,000-\$74,999, and ≥\$75,000. Body mass index (BMI, kg/m²) was 207 collected during examination at mobile examination center. Estimated glomerular 208 209 filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation, ²⁴ which estimates GFR for age, sex, and serum creatinine in 210 211 µmol/L. The eGFR can influence metabolite excretion in urine and was therefore used 212 for adjustment in our models. Total cholesterol and high-density lipoprotein (HDL) 213 cholesterol were measured in blood collected at mobile examination centers. Diabetes status was determined based on self-reported responses that the participant was ever 214 215 told by a doctor they had diabetes or were taking medications to lower blood sugar. Prevalent CVD status was determined based on self-reported responses that the 216 participant was ever told by a doctor they had congestive heart failure, coronary heart 217 disease, angina or angina pectoris, heart attack, or stroke. 218 219 220 **Statistics** Combined NHANES survey cycles and weights produce estimates representative of the 221

U.S. civilian noninstitutionalized population at the midpoint of the combined survey

223 period. We constructed new sample weights for the combined cycles (4 cycles, 2011-

224 2018) by multiplying 2-year subsample weights for environmental chemicals by 1/4 (for

²²⁵ 4 NHANES cycles) as described.²⁵

To characterize our study population, we stratified by hypertension status and 227 continuous and categorical variables of interest using t-tests and x² tests. We used 228 linear regression models for normally distributed BP and modified Poisson regression 229 with robust standard errors for dichotomous hypertension outcomes to estimate 230 prevalence ratios of hypertension.²⁶ Urine VOC metabolite levels were modeled as: (1) 231 quartiles (to compare each of the highest three quartiles to the lowest quartile), (2) per 232 interguartile range (IQR) on log-transformed levels (to compare the 75th to the 25th 233 percentile), and (3) log-transformed levels with restricted quadratic splines (to evaluate 234 235 the flexible dose-response relationship). Because NHANES represents a younger, more general population, we chose to adjust for sociodemographic factors age, sex, race and 236 ethnicity, education, eGFR, and NHANES cycle year and BMI in our main model, Model 237 1, as to not adjust away potential mediating CVD risk factors based on literature reviews 238 for BP and hypertension.^{27, 28} In Model 2, we further adjust for traditional CVD risk 239 factors including total cholesterol, HDL, triglycerides, diabetes status, and BP 240 medications. We present 9 priority urinary VOC metabolites of parent VOCs acrolein, 241 benzene, 1,3-butadiene, crotonaldehyde, and styrene, from Model 1, in the main text. 242 Model estimates are population weighted mean differences in BP or population 243 weighted prevalence ratio of hypertension with 95% confidence intervals (CI). All central 244 tendency estimates, proportions and effect estimates are population weighted. 245

246

247 Secondary analyses

In secondary analyses, we examined the other 12 VOC metabolites measured in
 NHANES. We used Wald tests and conducted subgroup analysis to assess effect
 modification by subgroups of age, sex, and race and ethnicity.

251

To address potential co-pollutant exposure and collinearity, we used hierarchical 252 253 Bayesian Kernel Machine Regression (BKMR). Because BKMR cannot account for complex survey weighting, we consider these exploratory analyses. BKMR is a kernel-254 regression based machine learning method that characterizes the exposure response 255 256 function of multiple predictors on a health outcome while other predictors are fixed to a specific percentile.^{29, 30} The method also allows us to examine statistical interactions 257 between VOC metabolites within the mixture and joint associations between the whole 258 mixture and health outcomes. The hierarchical BKMR uses hierarchical variable 259 selection to create posterior inclusion probabilities (PIPs) that quantify the relative 260 importance by selecting 1) at the group level and 2) by selecting exposures of each 261 group.²⁹ All metabolites with the same parent compound were grouped in hierarchical 262 analysis except for MHBMA3 and HPMMA which were more highly correlated than 263 264 DHBMA and MHBMA3 (Figure S2). We excluded the benzene metabolites, MU and PMA, due to missing cycles. BKMRs were run with 10,000 iterations and the tuning 265 parameter r.jump value of 0.1 for continuous SBP and DBP and dichotomous 266 267 hypertension to achieve higher acceptance rates.

268

269 Sensitivity Analyses

We conducted several sensitivity analyses. Because a number of participants reported
use of BP lowering medications, we assessed differences between measured and

underlying BP.³¹ For individuals self-reporting use of BP lowering medications we 272 imputed underlying BP values by adding a 10 mm Hg or 5 mm Hg constant to measured 273 SBP or DBP, respectively.³¹ Additionally, we assessed differences between Stage 1, 274 Stage 2, and physician-diagnosed hypertension. 275 276 Data analysis was performed in R (version 3.1.3)³² using the nhanesA³³, tidyverse³⁴ and 277 survey package³⁵ to account for the complex survey design and sampling weights. 278 279 RESULTS 280 The characteristics of NHANES participants by hypertension status are shown in Table 281 282 1. Participants were 54% female, with a median age of 48 years, 32.3% had hypertension, and 17.9% had diabetes mellitus. Participants with hypertension were 283 older and more likely to be non-Hispanic White or non-Hispanic Black, had higher BMI, 284 285 lower eGFR, lower HDL cholesterol, higher triglycerides, higher total cholesterol, and were more likely to have self-reported physician diagnosed CVD and diabetes mellitus. 286

Additionally, participants with hypertension had higher median levels of all priority

urinary VOC metabolites compared to participants without hypertension (Table 2 and

Table S2), except for the PMA benzene metabolite.

290

Results for priority VOC metabolites and BP outcomes are shown in Table 3. For
acrolein, the urinary metabolite CEMA was associated with higher SBP and a higher
prevalence of hypertension. When comparing the highest to lowest quartile, the mean
difference (MD) (95%CI) was 1.61 (0.07, 3.15) mmHg for SBP, and the prevalence ratio

(PR) (95%CI) of hypertension was 1.06 (1.02, 1.09). Estimates for SBP and 295 hypertension were also statistically significant per log IQR-change and, although 296 attenuated, generally remained significant after further adjustment for CVD risk factors. 297 In the restricted quadratic spline models, there were clear positive dose-response 298 relationships with SBP and PR of hypertension observed for CEMA above 34.20 ng/mg 299 300 creatinine (Figures 1 and 2). For the other acrolein metabolite, 3HPMA, results were positive but not significant for SBP (MD [95%CI]: 1.28 [-0.33, 2.90] mmHg); however, 301 the association with hypertension was statistically significant (PR [95%CI]: 1.05 [1.01, 302 303 1.09]).

304

Likewise, for 1,3-butadiene, the urinary metabolite DHBMA was associated with higher 305 SBP and a higher prevalence of hypertension. When comparing the highest to lowest 306 quartile of DHBMA, the MD in SBP was 2.46 (1.01, 3.92) mmHg and the PR of 307 hypertension was 1.05 (1.01, 1.09). Estimates for SBP and hypertension were also 308 statistically significant per log IQR-change and, although attenuated, generally remained 309 significant after further adjustment for CVD risk factors. The linear association apparent 310 311 in the quartile models was also observed with the restricted quadratic spline models, with clear positive dose-response relationships with SBP and PR of hypertension 312 observed for DHBMA above 252 ng/mg creatinine (Figures 1 and 2). For the other 1,3-313 314 butadiene metabolite, MHBMA3, results were less consistent, but there was an association with hypertension per log IQR of MHBMA3 (PR [95%CI]: 1.01 [1.00, 1.02]). 315 316

For the other priority metabolites, results were less consistent. The benzene metabolite. 317 MU, was associated with higher SBP per log IQR of MU (MD [95%CI]: 0.76 [0.05, 1.48] 318 mmHq), but not with higher prevalence of hypertension. When comparing the highest 319 guartile to the lowest guartile, the crotonaldehyde metabolite, HPMMA, and the styrene 320 metabolite, MA, were associated with higher prevalence of hypertension (PR [95%CI]: 321 322 1.06 [1.02, 1.10], and 1.05 [1.01, 1.08]), respectively. Estimates for HPMMA and MA and SBP trended positive but were not statistically significant. Additionally, we found no 323 significant results for any of the priority VOC metabolites and DBP (Table 3 and 324 325 Figure S3). Results for the other urinary VOC metabolites available in NHANES (i.e., parent compounds: acrylamide, acrylonitrile, 1-bromopropane, carbon disulfide, 326 cyanide, n,n-dimethylformamide, isoprene, propylene oxide, toluene, and xylene) are 327 reported in Table S3. 328

329

In Wald tests for interaction, we found significant interactions between age and all 330 priority VOC metabolites except for the benzene metabolite PMA (Table S4). 331 In models stratified by age groups for priority VOCs, the associations with SBP were 332 stronger for the age subgroup 40-64 for metabolites of benzene (MU), 1,3-butadiene 333 (DHBMA), and styrene (PGA). For hypertension, associations were stronger for the age 334 group 40-64 and \geq 65 for metabolites of acrolein (CEMA) and crotonaldehyde (HPMMA), 335 336 the age group 40-64 for the metabolites of benzene (MU) and styrene (PGA), and the age group \geq 65 for metabolites of 1,3-butadiene (MHBMA3) and styrene (MA). We found 337 338 significant interactions between sex and metabolites of acrolein, 1,3-butadiene, and 339 crotonaldehyde. By sex, the association with SBP was stronger in females for

340	metabolites of acrolein (CEMA, 3HPMA), 1,3-butadiene (DHBMA) and crotonaldehyde
341	(HPMMA). We found significant interactions between race and ethnicity for all VOC
342	metabolites except for the benzene metabolite PMA and the styrene metabolite PGA.
343	The association with SBP was stronger for Mexican Americans for 1,3-butadiene
344	(DHBMA), for Non-Hispanic Asians for acrolein (CEMA), and for Non-Hispanic Blacks
345	for styrene (MA). The association with hypertension was stronger for Non-Hispanic
346	Whites for metabolites of acrolein (3HPMA), benzene (MU), crotonaldehyde (HPMMA)
347	and styrene (MA). Patterns for other VOCs were inconsistent.
348	
349	In sensitivity analyses, we found that effect sizes of associations with underlying BP
350	were consistent with the main analyses of original, measured BP (data not shown).
351	Similarly, the use of Stage 2 or physician diagnosed definitions of hypertension did not
352	significantly change effect sizes; however, use of stage 1 hypertension outcome
353	attenuated associations, except for the styrene metabolite (MA) (Figure S4).
354	
355	Urinary VOC metabolites originating from the same parent compound were highly
356	correlated except for 1,3-butadiene metabolites, where MHBMA3 was more highly
357	correlated with crotonaldehyde metabolite, HPMMA (Figure S2). We found no
358	significant association between the VOC metabolite mixture and SBP (Figure S5).
359	However, the VOC mixture and overall risk of hypertension was significant and positive.
360	Conditional posterior inclusion probabilities were higher for acrolein metabolite, CEMA,
361	and 1,3-butadiene metabolite, DHBMA, for SBP and CEMA for hypertension (Table S5).
362	

363 DISCUSSION

364	In this nationally representative study of non-smoking adults, we found that the acrolein
365	metabolite, CEMA, and the 1,3-butadiene metabolite, DHBMA, were consistently and
366	significantly associated with higher SBP and higher prevalence of hypertension in
367	quartile, log IQR, and restricted spline models. The other priority VOC metabolites were
368	less consistent across BP outcomes. Estimates were attenuated after adjustment for
369	cardiovascular risk factors. Exploratory hierarchical BKMR analyses supported acrolein
370	and 1,3-butadiene as important contributors to SBP and hypertension risk and the
371	overall mixture of VOC metabolites (excluding benzene) was associated with
372	hypertension.
373	
374	Elevated BP is an important risk factor for the development of CVD and is associated
375	with the highest population attributable fraction for CVD deaths in the U.S. (40.6%). 36
376	Systolic hypertension is usually the result of arterial thickening and stiffening caused
377	either by atherosclerosis, medial degradation, or impaired endothelial-mediated
378	vasodilation, ³⁷ processes that have been shown to be sensitive to VOCs in experimental
379	studies. ^{14, 38} Taken together, these observations suggest that exposure to VOCs,
380	particularly acrolein and 1,3-butadiene, may be significant contributors to the
381	development of CVD, in the general non-smoking population.
382	
383	Among NHANES 2011-2018 participants the acrolein metabolite, CEMA, was
384	associated with higher SBP and prevalence of hypertension and the 3HPMA metabolite
385	was associated with higher prevalence of hypertension. Acrolein is a pesticide,

combustion byproduct, precursor in the production of other chemicals, and byproduct of 386 lipid peroxidation, glycation, and amino acid oxidation; 3HPMA and CEMA account for 387 about 30% of the dose from exposure.³⁹ Epidemiological evidence shows acrolein 388 metabolites are associated with SBP among nonsmoking adults, including in a cohort of 389 308 adults in Louisville, KY of mean age 51.7 years (MD [95%CI] CEMA: 1.2 [-0.3, 3.3] 390 mmHg and 3HPMA: 0.98 [0.04, 1.9] mmHg)¹⁴ and a cohort of 778 Black participants in 391 Jackson, MS of mean age 51.3 years (CEMA: 1.6 [0.4, 2.7] mmHg and 3HPMA: 0.8 392 [0.01. 1.6] mmHa).⁴⁰ However, associations between acrolein metabolites and 393 hypertension were null among participants in Jackson, MS. A 2022 analysis of ambient 394 VOC exposure in the Sister Study (n=47,467) found that ambient acrolein exposure was 395 associated with a greater risk of hypertension, particularly among never smoking 396 women 35-74 years of age.⁴¹ Likewise, in a nested case-cohort study of non-smoking 397 individuals in northeastern Iran (n=1,198), there was an increased hazard ratio of 398 ischemic heart disease mortality associated with metabolites of acrolein (CEMA, 2.11 399 (1.31, 3.40) and 3HPMA, 2.99 (1.60, 5.59)) when comparing the highest tertile to the 400 lowest.¹⁸ 401

402

In this study, we also found the 1,3-butadiene metabolite, DHBMA, was positively
associated with higher SBP and greater risk of hypertension, and MHBMA3 was
associated with higher prevalence of hypertension. Most human exposure from 1,3butadiene occurs from incomplete combustion of fossil fuels and burning of biomass.⁴²
DHBMA is the most abundant metabolite in urine due to its natural background, which
may be caused by endogenous sources.^{43, 44} It is unknown whether high background

levels of DHBMA are due to 1,3-butadiene exposures or endogenous sources like lipid 409 peroxidation. Additionally, crotonaldehyde is produced endogenously from the 410 metabolism of 1,3-butadiene and may contribute to higher levels of DHBMA.⁴⁵⁻⁴⁷ 411 Although MHBMA3 is a sensitive marker of 1,3-butadiene exposure, DHBMA is not a 412 sensitive marker.⁴⁸ and does not decrease with smoking cessation, compared to 413 MHBMA3.⁴⁹ Therefore. DHBMA may be a relevant biomarker for CVD risk.⁵⁰ but may 414 not be indicative of 1,3-butadiene exposure. In the Sister Study (n=47,467), ambient 415 1,3-butadiene at the census tract level was associated with 1.05 (95% CI 1.00, 1.10) 416 greater risk of hypertension.⁴¹ Additionally, there was a higher ischemic heart disease 417 mortality hazard ratio associated with 1,3-butadiene [DHBMA, 2.49 (1.50, 4.15)] in a 418 recent study of non-smoking northeastern Iranians (n=1.198).¹⁸ However, associations 419 were null among participants in the Louisville, KY and Jackson, MS studies.^{14, 40} More 420 studies of low-level 1,3-butadiene exposures are required to better assess the 421 sensitivity of DHBMA as an exposure biomarker. 422

423

The other priority metabolites were associated with either higher SBP or higher 424 prevalence of hypertension, but not both. The benzene metabolite, MU (but not PMA), 425 was associated with higher SBP. This may be due to smaller sample size compared 426 with the other VOC metabolites. Limited, consistent evidence exists of urinary benzene 427 metabolites and ambient benzene and cardiovascular outcomes due to ongoing 428 analytical issues.^{51, 52} In the Sister Study, ambient benzene was significantly associated 429 with a 1.06 (95% CI 1.01, 1.10) greater risk of hypertension among never smokers.⁴¹ 430 431 The crotonaldehyde metabolite, HPMMA, was associated with higher prevalence of

hypertension. Among nonsmoking Black participants in Jackson, MS, HPMMA was 432 associated with higher SBP (MD: 1.2 [95%CI: 0.08, 1.8] mm Hg),⁴⁰ but associations with 433 hypertension were null. Similarly, results for HPMMA and BP were null in the Louisville, 434 KY cohort.¹⁴ The styrene metabolite, MA (but not PGA), was associated with higher 435 prevalence of hypertension. Consistent with our results, the Consortium of Safe Labor 436 437 showed that ambient styrene was associated with greater odds of hypertension and higher SBP and DBP among normotensive women.^{53, 54} Additionally, two longitudinal 438 studies of occupational co-exposure to 1,3-butadiene and styrene have shown 439 440 increased standardized mortality ratios for arteriosclerotic heart disease in non-White populations:⁵⁵⁻⁵⁷ there was no data on only styrene exposure. However, in the recent 441 case-cohort study in Iran, there was an increased risk of ischemic heart disease 442 mortality associated with both metabolites of styrene [MA, 1.94 (1.18, 3.20) and PGA, 443 1.54 (1.00, 2.37)].¹⁸ 444

445

446 Limitations & Future Direction

This large study of VOC metabolites and blood pressure in a representative population 447 of U.S. adults included 4,430 nonsmoking participants and evaluated 35 different VOC 448 metabolites in urine. To minimize error from multiple testing, we prioritized nine VOC 449 metabolites from five parent VOCs, acrolein, benzene, 1.3-butadiene, crotonaldehvde, 450 and styrene, based on prior evidence. All VOC metabolites with >50% observations 451 above LOD available in NHANES, however, were explored in secondary analyses. 452 453 Previous studies have measured VOCs in air and grouped them by structure, functional group, or as a measure of total VOCs; here, we used stable urinary metabolites of VOC 454 exposure, a robust measure of short-term exposure. The existing literature has been 455

456	limited by the sample size of non-smokers with measured VOC metabolites. By
457	combining 4 cycles of NHANES we increased the non-smoking sample size resulting in
458	the largest study of VOC metabolites and BP among the general, non-smoking US
459	population. Because metabolites from the same parent VOCs are highly correlated, we
460	used hierarchical BKMR to confirm single-pollutant models after taking correlated VOC
461	co-exposures into account, as well as determined the effects of VOC mixtures on BP
462	and hypertension. These mixture analyses were only exploratory as a weighting
463	scheme for complex survey designs has not yet been developed for BKMR.
464	
465	Other limitations include the cross-sectional design and potential for exposure
466	misclassification. Data from other cohorts designed to study cardiovascular health, like
467	the Multi-Ethnic Study of Atherosclerosis, may help elucidate differences in
468	cardiovascular risk among VOC exposure groups, particularly with a longitudinal design
469	to evaluate changes in BP levels and hypertension risk over time.

470 **PERSPECTIVES**

This study in NHANES found that metabolites of acrolein and 1,3-butadiene were
associated with higher SBP and risk of hypertension, in the non-smoking, general US
population. Additional research is needed to characterize the contribution of nonsmoking related environmental VOC exposures to cardiovascular risk and to develop
policy and interventions to curb preventable exposure to VOCs and further reduce the
risk of CVD.

478

479 NOVELTY AND RELEVANCE

480 What is New?

481	This is the largest biomonitoring study of VOC exposure and elevated blood
482	pressure in the general, non-smoking U.S. population.
483	VOCs present in the environment and/or endogenous VOCs are associated with
484	higher systolic BP and greater prevalence of hypertension.
485	
486	What is Relevant?
487	• VOC exposure, independent of cigarette smoking, may contribute to the growing
488	prevalence of cardiovascular diseases
489	
490	Clinical/Pathophysiological Implications
491	Reduction of VOC exposure may improve cardiovascular health.

493 ACKNOWLEDGEMENTS

- 494 Data and materials produced by Federal agencies are in the public domain and may be
- reproduced without permission. However, the authors would like to thank participants in
- the National Health and Nutrition Examination Surveys (NHANES).

497 SOURCES OF FUNDING

- 498 Work in the authors' laboratories is supported by NIEHS grants P42ES023716,
- 499 P42ES033719, P30ES009089, R01ES029967, and T32ES00732221.

500 **DISCLOSURES**

501 The authors have no conflicts of interest to disclose.

502 SUPPLEMENTAL MATERIAL

503 Tables S1-S5 504 Figures S1-S5

506 **REFERENCES**

- McDonald BC, de Gouw JA, Gilman JB, Jathar SH, Akherati A, Cappa CD, et al. Volatile
 chemical products emerging as largest petrochemical source of urban organic emissions.
 Science (New York, N.Y.). 2018;359:760-764
 Landrigan PJ, Fuller R, Acosta NJR, Adeyi O, Arnold R, Basu NN, et al. The lancet commission on pollution and health. *Lancet (London, England).* 2018;391:462-512
 Armor JN. Volatile organic compounds: An overview. *Environmental catalysis.* American
- 5143.Armor JN. Volatile organic compounds: An overview. Environmental catalysis. American515Chemical Society; 1994:298-300.
- United States Environmental Protection Agency U. Volatile organic compounds emissions. *Report* on the Environment.
- 5. Jerrett M, Burnett RT, Pope CA, Ito K, Thurston G, Krewski D, et al. Long-term ozone exposure and mortality. *New England Journal of Medicine*. 2009;360:1085-1095
- 520 6. Jimenez JL, Canagaratna MR, Donahue NM, Prevot ASH, Zhang Q, Kroll JH, et al. Evolution of 521 organic aerosols in the atmosphere. *Science (New York, N.Y.)*. 2009;326:1525
- 522 7. Danforth CG, Portier C, Ensor KB, Hopkins L, Evans B, Quist AJL, et al. Development and
 523 demonstration of a data visualization platform of short-term guidelines for ambient air levels of
 524 benzene during disaster response in houston, tx. *Integrated Environmental Assessment and* 525 *Management*.n/a
- 526 8. U.S. Environmental Protection Agency. Technical overview of volatile organic compounds. *Indoor* 527 *Air Quality*. 2017;2019
- 528 9. Kehrer JP, Biswal SS. The molecular effects of acrolein. *Toxicol Sci.* 2000;57:6-15
- 529 10. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, 530 malonaldehyde and related aldehydes. *Free Radic Biol Med*. 1991;11:81-128
- 53111.Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med.5322000;28:1685-1696
- Xu X, Freeman NC, Dailey AB, Ilacqua VA, Kearney GD, Talbott EO. Association between
 exposure to alkylbenzenes and cardiovascular disease among national health and nutrition
 examination survey (nhanes) participants. *International journal of occupational and environmental health.* 2009;15:385-391
- 537 13. Shim YH, Ock JW, Kim Y-J, Kim Y, Kim SY, Kang D. Association between heavy metals,
 538 bisphenol a, volatile organic compounds and phthalates and metabolic syndrome. *Int J Environ*539 *Res Public Health.* 2019;16:671
- McGraw KE, Riggs DW, Rai S, Navas-Acien A, Xie Z, Lorkiewicz P, et al. Exposure to volatile
 organic compounds acrolein, 1,3-butadiene, and crotonaldehyde is associated with vascular
 dysfunction. *Environmental Research*. 2021:110903
- 15. McGraw KEaK, Stacey L. and Riggs, Daniel W. and Rai, Shesh N. and DeJarnett, Natasha K.
 and Xie, Zhengzhi and Keith, Rachel J. and Oshunbade, Adebamike A. and Hall, Michael E. and
 Shimbo, Daichi and Bhatnagar, Aruni. . Exposure to volatile organic compounds is associated
 with hypertension in black adults: The jackson heart study. . *Available at SSRN*. 2022
- 547 16. DeJarnett N, Conklin DJ, Riggs DW, Myers JA, O'Toole TE, Hamzeh I, et al. Acrolein exposure is associated with increased cardiovascular disease risk. *Journal of the American Heart*549 Association. 2014;3
- 55017.Abplanalp W, DeJarnett N, Riggs DW, Conklin DJ, McCracken JP, Srivastava S, et al. Benzene551exposure is associated with cardiovascular disease risk. *PloS one*. 2017;12:e0183602
- Nalini M, Poustchi H, Bhandari D, Chang CM, Blount BC, Wang L, et al. Volatile organic
 compounds and mortality from ischemic heart disease: A case-cohort study. *American Journal of Preventive Cardiology*. 2024:100700
- Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017
 acc/aha/aapa/abc/acpm/ags/apha/ash/aspc/nma/pcna guideline for the prevention, detection,
 evaluation, and management of high blood pressure in adults: A report of the american college of
 cardiology/american heart association task force on clinical practice guidelines. *Hypertension*.
 2018;71:e13-e115

560	20.	U.S. Department of Health and Human Services. National health and nutrition examination
562	21.	Centers for Disease Control and Prevention (CDC). National health and nutrition examination
563		survey data. 2011-2018
564	22.	centers for Disease Control and Prevention (CDC). Laboratory procedure manual. Antimony.
565		Arsenic, Barium, Beryllium, Cadmium, Cesium, Cobalt, Lead, Manganese, Molybdenum,
566		Platinum, Strontium, Thallium, Tin, Tungsten, and Uranium, 2012:63
567	23.	Centers for Disease Control and Prevention C. Laboratory procedure manual: Volatile organic
568		compound (vocs) metabolites. 2011
569	24.	Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and
570		cystatin c-based equations to estimate gfr without race. New England Journal of Medicine.
571		2021;385:1737-1749
572	25.	Centers for Disease Control and Prevention (CDC). Module 3: Weighting. National Health and
573		Nutrition Examination Survey. 2022
574	26.	Zou G. A modified poisson regression approach to prospective studies with binary data. American
575		Journal of Epidemiology. 2004;159:702-706
576	27.	Fox ER, Samdarshi TE, Musani SK, Pencina MJ, Sung JH, Bertoni AG, et al. Development and
577		validation of risk prediction models for cardiovascular events in black adults: The jackson heart
578		study cohort. JAMA Cardiology. 2016;1:15-25
579	28.	Forde AT, Sims M, Muntner P, Lewis T, Onwuka A, Moore K, et al. Discrimination and
580		hypertension risk among african americans in the jackson heart study. Hypertension.
581		2020;76:715-723
582	29.	Bobb JF, Valeri L, Claus Henn B, Christiani DC, Wright RO, Mazumdar M, et al. Bayesian kernel
583		machine regression for estimating the health effects of multi-pollutant mixtures. <i>Biostatistics</i> .
584		2015;16:493-508
585	30.	Bobb JF. Bayesian kernel machine regression [r package bkmr
586	versior	n 0.2.0]. 2017
587	31.	Balakrishnan P, Beaty T, Young JH, Colantuoni E, Matsushita K. Methods to estimate underlying
588		blood pressure: The atherosclerosis risk in communities (aric) study. <i>PloS one</i> .
589		2017;12:e0179234-e0179234
590	32.	R Core Team. R: A language and environment for statistical computing. R Foundation for
591		Statistical Computing, Vienna, Austria. 2019
592	33.	Endres CJ. Nhanesa: Nhanes data retrieval. 2019
593	34.	Wickham et al. Welcome to the tidyverse. Journal of Open Source Software. 2019;4
594	35.	Lumley T. Complex surveys: A guide to analysis using r: A guide to analysis using r. 2010
595	36.	Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, et al. Trends in
596		cardiovascular health metrics and associations with all-cause and cvd mortality among us adults.
597		JAMA. 2012;307:1273-1283
598	37.	Mitchell GF, Conlin PR, Dunlap ME, Lacourcière Y, Arnold JM, Ogilvie RI, et al. Aortic diameter,
599		wall stiffness, and wave reflection in systolic hypertension. <i>Hypertension</i> . 2008;51:105-111
600	38.	Conklin DJ. Acute cardiopulmonary toxicity of inhaled aldehydes: Role of trpa1. Annals of the
601		New York Academy of Sciences. 2016;1374:59-67
602	39.	Stevens JF, Maier CS. Acrolein: Sources, metabolism, and biomolecular interactions relevant to
603		human health and disease. Molecular nutrition & food research. 2008;52:7-25
604	40.	McGraw KE, Konkle SL, Riggs DW, Rai SN, DeJarnett N, Xie Z, et al. Exposure to volatile
605		organic compounds is associated with hypertension in black adults: The jackson heart study.
606		Environmental Research. 2023;223:115384
607	41.	Xu J, Niehoff NM, White AJ, Werder EJ, Sandler DP. Fossil-fuel and combustion-related air
608	10	pollution and hypertension in the sister study. <i>Environ Pollut</i> . 2022;315:120401
609	42.	Walker VE, Degner A, Carter EW, Nicklas JA, Walker DM, Tretyakova N, et al. 1,3-butadiene
610		metabolite 1,2,3,4 diepoxybutane induces DNA adducts and micronuclei but not t(9;22)
611	40	translocations in numan cells. Chemico-Biological Interactions. 2019;312:108797
612	43.	Boogaard PJ, van Sittert NJ, Megens HJ. Urinary metabolites and haemoglobin adducts as
613		biomarkers of exposure to 1,3-butadiene: A basis for 1,3-butadiene cancer risk assessment.
614		Chem Biol Interact. 2001;135-136:695-701

- 44. van Sittert NJ, Megens HJ, Watson WP, Boogaard PJ. Biomarkers of exposure to 1,3-butadiene
 as a basis for cancer risk assessment. *Toxicol Sci.* 2000;56:189-202
- 617 45. Conklin DJ, Ogunwale MA, Chen Y, Theis WS, Nantz MH, Fu X-A, et al. Electronic cigarette618 generated aldehydes: The contribution of e-liquid components to their formation and the use of
 619 urinary aldehyde metabolites as biomarkers of exposure. *Aerosol Sci Technol.* 2018;52:1219620 1232
- 46. Grant RL, Jenkins AF. Use of in vivo and in vitro data to derive a chronic reference value for
 crotonaldehyde based on relative potency to acrolein. *Journal of toxicology and environmental health. Part B, Critical reviews.* 2015;18:327-343
- 47. National Center for Biotechnology Information. Crotonaldehyde.CID=447466
- 48. Carrieri M, Bartolucci GB, Paci E, Sacco P, Pigini D, Zaratin L, et al. Validation of a radial diffusive sampler for measuring occupational exposure to 1,3-butadiene. *Journal of Chromatography A*. 2014;1353:114-120
- 628 49. Carmella ŠG, Chen M, Han S, Briggs A, Jensen J, Hatsukami DK, et al. Effects of smoking
 629 cessation on eight urinary tobacco carcinogen and toxicant biomarkers. *Chem Res Toxicol.*630 2009;22:734-741
- 50. Lin C-Y, Lee H-L, Jung W-T, Sung F-C, Su T-C. The association between urinary levels of 1,3butadiene metabolites, cardiovascular risk factors, microparticles, and oxidative stress products in adolescents and young adults. *Journal of Hazardous Materials*. 2020;396:122745
- 51. Tevis DS, Willmore A, Bhandari D, Bowman B, Biren C, Kenwood BM, et al. Large differences in urinary benzene metabolite s-phenylmercapturic acid quantitation: A comparison of five lc–ms-ms methods. *Journal of Analytical Toxicology*. 2020;45:657-665
- 63752.National Health and Nutrition Examination Survey. Volatile organic compound (voc) metabolites -638urine (uvoc_g). 2011-2012 Data Documentation, Codebook, and Frequencies. 2011-2012
- Mannisto T, Mendola P, Liu D, Leishear K, Sherman S, Laughon SK. Acute air pollution exposure
 and blood pressure at delivery among women with and without hypertension. *Am J Hypertens*.
 2015;28:58-72
- 64254.Zhu Y, Zhang C, Liu D, Ha S, Kim SS, Pollack A, et al. Ambient air pollution and risk of643gestational hypertension. Am J Epidemiol. 2017;186:334-343
- 64455.Matanoski GM, Santos-Burgoa C, Schwartz L. Mortality of a cohort of workers in the styrene-645butadiene polymer manufacturing industry (1943-1982). Environ Health Perspect. 1990;86:107-646117
- 56. Divine BJ, Hartman CM. Mortality update of butadiene production workers. *Toxicology*.
 1996;113:169-181
- 649 57. Matanoski GM, Tao X. Styrene exposure and ischemic heart disease: A case-cohort study.
 650 American Journal of Epidemiology. 2003;158:988-995
- 651
- 652

653 **TABLES**

654

Table 1. Participant characteristics across categories of hypertension, restricted to nonsmoking participants with available blood pressure examination data and urinary VOCs,

n=4,430 NHANES 2011-2018 participants. Continuous variables are reported as

median [interquartile range, IQR] and categorical variables as number (%). Percentages

are population weighted.

	Overall	No Hypertension	Hypertension
n	4,430	2,819	1,611
Age (years)	48 [33, 62]	40 [28, 54]	62 [54, 71]
Sex			
Male	2,044 (46.0)	1,259 (45.3)	785 (47.5)
Female	2,386 (54.0)	1,560 (54.7)	826 (52.5)
Race/Ethnicity			
Mexican American	681 (9.6)	494 (11.3)	187 (6.1)
Other Hispanic	533 (7.3)	369 (8.4)	164 (5.0)
Non-Hispanic White	1,540 (64.8)	943 (62.8)	597 (69.0)
Non-Hispanic Black	868 (9.7)	449 (8.3)	419 (12.6)
Non-Hispanic Asian	679 (6.3)	478 (6.8)	201 (5.2)
Other Race, incl Multi	129 (2.4)	86 (2.5)	43 (2.2)
Education			
Less than HS Diploma	884 (12.2)	500 (11.3)	384 (14.0)
High School Grad/GED	926 (20.7)	553 (19.3)	373 (23.6)
Some College	1,329 (31.1)	841 (30.1)	488 (33.3)
College Degree or More	1,291 (36.0)	925 (39.4)	366 (28.9)
Income			
\$0-\$24,999	1,002 (15.9)	563 (14.6)	439 (18.7)
\$25,000-\$54,999	1,308 (29.1)	828 (29.4)	480 (28.5)
\$55,000-\$74,999	490 (13.1)	335 (13.4)	155 (12.4)
≥\$75,000	1,352 (41.9)	913 (42.7)	439 (40.4)
BMI (kg/m²)	28.3 [24.5, 33.0]	27.2 [23.7, 31.7]	30.7 [26.6, 35.8]
Serum Cotinine (ng/mL)	0.02 [0.01, 0.05]	0.02 [0.01, 0.05]	0.02 [0.01, 0.04]
eGFR (mL/min/1.73 m²)	97.6 [82.0, 111.9]	103.3 [88.4, 116.7]	86.2 [68.9, 98.9]
HDL (mg/dL)	53.0 [43.0, 63.0]	53.3 [44.0, 64.0]	50.0 [41.0, 61.0]
Triglycerides (mg/dL)	115.0 [77.0, 176.0]	104.0 [72.0, 165.0]	134.0 [94.0, 206.0]
Total Cholesterol (mg/dL)	186.0 [161.0, 214.0]	185.0 [160.0, 213.0]	191.5 [163.0, 218.0]
SBP (mmHg)	120.0 [110.7, 132.0]	114.7 [107.3, 123.3]	136.0 [124.0, 147.3]
DBP (mmHg)	71.3 [64.7, 78.0]	70.0 [64.0, 76.0]	75.3 [66.7, 84.0]
Underlying SBP (mmHg) ^a	122.0 [111.3, 135.3]	114.7 [107.3, 123.3]	142.7 [133.3, 152.7]
Underlying DBP (mmHg) ^b	72.3 [65.3, 79.3]	70.0 [64.0, 76.0]	79.0 [71.0, 87.0]
Hypertension Stage 1 ^c	2,201 (46.9)	590 (21.5)	1,611 (100.0)
Hypertension MDDX ^d	1,542 (31.2)	216 (7.0)	1,326 (81.9)
CVD ^e	382 (7.6)	100 (3.8)	282 (15.3)

Diabetes Mellitus ^f	439 (7.9)	126 (3.1)	313 (17.9)
BP Medications	1,213 (24.1)	0 (0.0)	1,213 (74.5)

^a Underlying Systolic Blood Pressure: a 10 mmHg constant was added to SBP

662 measurement of NHANES participants who self-report taking BP medications ^b

663 Underlying Diastolic Blood Pressure: a 5 mmHg constant was added to SBP

664 measurement of NHANES participants who self-report taking BP medications

⁶⁶⁵ ^c Hypertension Stage 1 is defined as mean SBP \ge 130 mmHg, DBP \ge 80 mm Hg, or

666 taking BP medications

^d Hypertension MDDX is defined as physician-diagnosed hypertension

^e CVD is defined if a physician has ever told you have congestive heart failure, coronary

- 669 heart disease, angina, heart attack, or stroke
- ^f Diabetes Mellitus is defined if a physician ever told you have diabetes mellitus or self-
- 671 report of taking diabetes medications
- 672

Table 2. Median and interquartile ranges of VOC metabolite levels (ng/mg creatinine)

across categories of hypertension, restricted to participants with available blood

676 pressure examination data and urinary VOCs, among 4,430 NHANES 2011-2018

participants. MU was measured in n=1,046 NHANES 2017-2018 participants and PMA

was measured in n=3,207 NHANES 2011-2016 participants.

679

Parent	Short ^a	Overall	No Hypertension	Hypertension
		4,430	2,819	1,611
Acrolein	CEMA	82.3 [54.5, 128.2]	76.2 [50.4, 116.7]	96.7 [64.5, 150.4]
Acrolein	3HPMA	193.7 [130.4, 297.6]	189.6 [127.4, 290.0]	202.8 [137.6, 310.8]
Benzene	MU ^b	44.8 [26.8, 93.0]	43.3 [24.5, 93.0]	47.7 [29.0, 93.1]
Benzene	PMA ^c	0.7 [0.5, 1.2]	0.8 [0.4, 1.3]	0.7 [0.5, 1.1]
1,3-Butadiene	DHBMA	300.0 [236.3, 385.1]	288.6 [227.5, 363.5]	340.1 [264.1, 429.8]
1,3-Butadiene	MHBMA3	3.9 [2.6, 6.0]	3.7 [2.5, 5.9]	4.2 [2.9, 6.2]
Crotonaldehyde	HPMMA	185.5 [143.0, 264.6]	173.6 [136.9, 250.0]	212.7 [159.3, 298.8]
Styrene	PGA	197.8 [148.5, 260.4]	190.6 [142.1, 251.0]	214.1 [158.4, 281.3]
Styrene	MA	122.4 [89.5, 164.4]	120.2 [88.9, 159.2]	128.4 [91.9, 172.9]

^a Metabolite long names: CEMA, N-Acetyl-S-(2-carboxyethyl)-L-cysteine; 3HPMA, N-

681 Acetyl-S-(3-hydroxypropyl)-L-cysteine; PMA, N-Acetyl-S-(phenyl)-L-cysteine; MU, *t*,*t*-

Muconic Acid; DHBMA, N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine; MHBMA3, N-Acetyl-

683 S-(4-hydroxy-2-butenyl)-L-cysteine; HPMMA, N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-

684 cysteine; PGA, Phenylglyoxylic acid; MA, Mandelic acid

^b MU was measured in n=1,046 NHANES 2017-2018 participants, n=604 did not have

686 hypertension and n=442 did have hypertension

^c PMA was measured in n=3,207 NHANES 2011-2016 participants, n=2,104 did not

have hypertension and n=1,103 did have hypertension

Table 3. Mean differences (95% confidence interval) of systolic blood pressure (SBP), diastolic blood pressure (DBP),

and prevalence ratios – PR (95% confidence interval) of hypertension by levels (ng/mg creatinine) of urinary VOC

691 metabolites, restricted to participants with available blood pressure examination data and urinary VOCs, n=4,430

NHANES 2011-2018 participants. MU was measured in n=1,046 NHANES 2017-2018 participants and PMA was

measured in n=3,207 NHANES 2011-2016 participants. Model 1 was adjusted for age, sex, race and ethnicity, education,

694 BMI, eGFR, and NHANES cycle year. Model 2 was additionally adjusted for HDL-cholesterol, triglycerides, total

695 cholesterol, diabetes status, and antihypertensive medication.

		SBP		DBP		Hypertension	
		Model 1	Model 2	Model 1	Model 2	Model 1	Model 2
Acrolein, CEMA	Ν						
Q1 (3.64, 56.33)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (56.34, 85.00)	1,107	0.24 (-1.19, 1.67)	0.00 (-1.41, 1.41)	0.85 (-0.23, 1.94)	0.63 (-0.48, 1.73)	1.01 (0.98, 1.05)	1.00 (0.98, 1.03)
Q3 (85.06, 128.2)	1,107	0.56 (-1.03, 2.15)	0.09 (-1.38, 1.55)	0.34 (-0.84, 1.52)	-0.07 (-1.20, 1.05)	1.03 (0.99, 1.07)	1.01 (0.98, 1.04)
Q4 (128.3, 4353)	1,108	1.61 (0.07, 3.15)	0.8 (-0.77, 2.37)	0.32 (-0.88, 1.53)	-0.13 (-1.22, 0.95)	1.06 (1.02, 1.09)	1.01 (0.99, 1.03)
p75 vs p25	4,430	0.95 (0.17, 1.73)	0.53 (-0.25, 1.3)	0.15 (-0.37, 0.67)	-0.09 (-0.55, 0.37)	1.03 (1.01, 1.05)	1.00 (1.00, 1.01)
Acrolein, 3HPMA							
Q1 (6.81, 133.33)	1,110	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (133.45, 197.8)	1,105	0.14 (-1.16, 1.43)	-0.11 (-1.41, 1.18)	-0.93 (-2.04, 0.18)	-1.02 (-2.12, 0.09)	1.02 (0.99, 1.05)	1.00 (0.98, 1.02)
Q3 (198.0, 307.2)	1,107	0.56 (-0.98, 2.10)	0.55 (-1.01, 2.12)	-0.77 (-2.00, 0.46)	-0.6 (-1.77, 0.57)	1.02 (0.99, 1.06)	1.01 (0.99, 1.04)
Q4 (307.3, 7947)	1,108	1.28 (-0.33, 2.90)	1.06 (-0.62, 2.74)	-0.34 (-1.76, 1.09)	-0.24 (-1.60, 1.12)	1.05 (1.01, 1.09)	1.02 (0.99, 1.05)
p75 vs p25	4,430	0.41 (-0.31, 1.13)	0.35 (-0.38, 1.09)	-0.18 (-0.80, 0.43)	-0.13 (-0.71, 0.46)	1.02 (1.00, 1.03)	1.00 (0.99, 1.01)
Benzene, MU							
Q1 (6.74, 24.23)	262	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (24.24, 42.54)	261	2.29 (-0.20, 4.78)	1.93 (-0.93, 4.79)	2.50 (0.33, 4.68)	1.95 (-0.32, 4.22)	1.01 (0.92, 1.10)	1.01 (0.96, 1.07)
Q3 (42.77, 84.86)	261	3.29 (-0.25, 6.82)	2.78 (-0.22, 5.79)	1.04 (-1.88, 3.97)	0.36 (-1.97, 2.69)	1.01 (0.92, 1.10)	1.01 (0.95, 1.08)
Q4 (85.14, 9294)	262	2.75 (-0.65, 6.15)	2.36 (-0.74, 5.45)	-1.32 (-4.09, 1.46)	-1.99 (-4.37, 0.39)	1.01 (0.95, 1.08)	1.01 (0.96, 1.07)
p75 vs p25	1,046	0.76 (0.05, 1.48)	0.65 (-0.04, 1.35)	-0.11 (-0.56, 0.35)	-0.28 (-0.65, 0.08)	1.00 (0.98, 1.02)	1.00 (0.99, 1.01)
Benzene, PMA							
Q1 (0.09, 0.420)	809	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)

Q2 (0.424, 0.695)	804	0.73 (-1.26, 2.73)	0.79 (-1.19, 2.77)	0.12 (-1.13, 1.36)	0.42 (-0.84, 1.68)	1.03 (0.98, 1.08)	1.01 (0.97, 1.04)
Q3 (0.70, 1.145)	801	1.09 (-0.80, 2.97)	1.05 (-0.86, 2.96)	0.94 (-0.39, 2.27)	0.98 (-0.28, 2.23)	1.01 (0.97, 1.05)	1.01 (0.98, 1.04)
Q4 (1.146, 13.00)	793	1.44 (-0.60, 3.47)	1.46 (-0.65, 3.57)	0.76 (-0.51, 2.02)	0.95 (-0.29, 2.19)	1.00 (0.96, 1.03)	0.99 (0.96, 1.02)
p75 vs p25	3,207	1.14 (-0.85, 3.13)	1.17 (-0.84, 3.17)	0.77 (-0.37, 1.92)	0.86 (-0.23, 1.96)	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)
1,3-Butadiene, DHBM	A						
Q1 (2.75, 229.59)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (229.62, 294.12)	1,111	1.15 (-0.44, 2.75)	1.08 (-0.45, 2.60)	-0.31 (-1.18, 0.55)	-0.26 (-1.12, 0.60)	1.02 (0.99, 1.05)	1.01 (0.98, 1.03)
Q3 (294.14, 375.0)	1,104	0.84 (-0.74, 2.42)	0.64 (-0.96, 2.25)	0.02 (-1.11, 1.14)	0.06 (-1.08, 1.21)	1.03 (0.99, 1.07)	1.00 (0.98, 1.03)
Q4 (375.29, 3800)	1,107	2.46 (1.01, 3.92)	2.35 (0.91, 3.79)	-0.87 (-2.05, 0.32)	-0.65 (-1.76, 0.46)	1.05 (1.01, 1.09)	1.02 (1.00, 1.05)
p75 vs p25	4,430	2.95 (1.06, 4.85)	2.93 (1.14, 4.72)	-0.49 (-1.94, 0.96)	-0.18 (-1.56, 1.19)	1.01 (1.00, 1.02)	1.01 (1.00, 1.02)
1,3-Butadiene, MHBM	A3						
Q1 (0.21, 2.636)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (2.642, 3.85)	1,110	1.48 (-0.17, 3.12)	1.18 (-0.38, 2.73)	-0.84 (-1.72, 0.04)	-0.91 (-1.76, -0.05)	1.04 (1.01, 1.08)	1.02 (1.00, 1.04)
Q3 (3.86, 5.97)	1,104	-0.14 (-1.76, 1.47)	-0.24 (-1.76, 1.27)	-1.09 (-2.18, 0.01)	-0.96 (-2.00, 0.08)	1.02 (0.99, 1.05)	1.00 (0.98, 1.02)
Q4 (5.98, 328.4)	1,108	0.60 (-0.74, 1.95)	0.51 (-0.87, 1.90)	-0.54 (-1.80, 0.72)	-0.50 (-1.73, 0.73)	1.03 (0.99, 1.06)	1.01 (0.99, 1.04)
p75 vs p25	4,430	0.02 (-0.48, 0.52)	0.01 (-0.50, 0.52)	-0.23 (-0.74, 0.28)	-0.20 (-0.71, 0.30)	1.01 (1.00, 1.02)	1.00 (1.00, 1.01)
Crotonaldehyde, HPM	MA						
Q1 (1.19, 140.31)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (140.32, 185.0)	1,108	1.00 (-0.76, 2.76)	0.63 (-1.20, 2.47)	1.13 (0.03, 2.23)	0.95 (-0.12, 2.03)	1.01 (0.98, 1.05)	0.99 (0.97, 1.02)
Q3 (185.1, 265.85)	1,106	1.25 (-0.19, 2.70)	0.69 (-0.81, 2.19)	0.68 (-0.63, 1.98)	0.64 (-0.67, 1.94)	1.05 (1.02, 1.08)	1.00 (0.98, 1.03)
Q4 (265.91, 10947)	1,108	1.27 (-0.46, 3.00)	0.73 (-1.11, 2.57)	0.3 (-1.14, 1.74)	0.43 (-0.94, 1.81)	1.06 (1.02, 1.10)	1.01 (0.98, 1.04)
p75 vs p25	4,430	0.29 (-0.79, 1.37)	0.10 (-1.02, 1.23)	-0.17 (-1.10, 0.76)	-0.06 (-0.92, 0.79)	1.01 (0.99, 1.02)	1.00 (1.00, 1.01)
Styrene, PGA							
Q1 (3.94, 139.39)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (139.41, 188.52)	1,107	-1.25 (-3.26, 0.75)	-1.02 (-3.03, 0.99)	-0.70 (-2.07, 0.67)	-0.42 (-1.73, 0.89)	1.00 (0.96, 1.03)	0.99 (0.96, 1.01)
Q3 (188.57, 250.0)	1,116	-0.85 (-2.28, 0.57)	-0.77 (-2.22, 0.67)	-0.36 (-1.78, 1.06)	-0.18 (-1.53, 1.17)	0.99 (0.96, 1.03)	0.99 (0.97, 1.02)
Q4 (250.41, 32525)	1,099	0.24 (-1.85, 2.33)	0.05 (-2.05, 2.16)	-1.02 (-2.51, 0.48)	-1.04 (-2.50, 0.42)	1.02 (0.98, 1.06)	1.01 (0.98, 1.03)
p75 vs p25	4,430	0.34 (-0.73, 1.41)	0.10 (-0.98, 1.18)	-0.18 (-1.08, 0.72)	-0.25 (-1.12, 0.63)	1.00 (0.99, 1.01)	1.00 (0.99, 1.00)

Styrene, MA

Q1 (4.17, 87.61)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (87.62, 121.31)	1,107	-0.96 (-2.61, 0.68)	-0.75 (-2.38, 0.89)	-1.47 (-2.62, -0.32)	-1.32 (-2.35, -0.29)	0.99 (0.96, 1.02)	1.00 (0.98, 1.03)
Q3 (121.32, 163.12)	1,107	0.84 (-0.66, 2.34)	0.67 (-0.76, 2.10)	0.23 (-1.12, 1.58)	0.14 (-1.14, 1.42)	1.00 (0.97, 1.03)	1.00 (0.98, 1.03)
Q4 (163.13, 27778)	1,108	1.28 (-0.50, 3.06)	1.12 (-0.63, 2.87)	0.36 (-1.01, 1.73)	0.45 (-0.81, 1.70)	1.05 (1.01, 1.08)	1.03 (1.01, 1.06)
p75 vs p25	4,430	0.85 (-0.33, 2.02)	0.56 (-0.62, 1.74)	0.51 (-0.29, 1.32)	0.48 (-0.25, 1.20)	0.98 (0.95, 1.02)	1.00 (0.97, 1.02)

697

- 698 Metabolite long names: CEMA, N-Acetyl-S-(2-carboxyethyl)-L-cysteine; 3HPMA, N-Acetyl-S-(3-hydroxypropyl)-L-cysteine;
- 699 PMA, N-Acetyl-S-(phenyl)-L-cysteine; MU, *t,t*-Muconic Acid; DHBMA, N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine;
- 700 MHBMA3, N-Acetyl-S-(4-hydroxy-2-butenyl)-L-cysteine; HPMMA, N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine;
- 701 PGA, Phenylglyoxylic acid; MA, Mandelic acid

703 FIGURES

704

Figure 1. Mean differences (MD) (95% confidence interval) of systolic blood pressure 705 (SBP) by urinary VOC levels (ng/mg creatinine) modeled as restricted quadratic splines 706 707 for priority VOC metabolites among nonsmoking NHANES 2011-2018 participants (n=4,430). Lines (shaded areas) represent the MD (95%CI) of SBP and RR (95% CI) of 708 hypertension by VOC metabolites modeled as restricted quadratic splines for log 709 transformed VOC metabolite distributions with knots at 10th, 50th, and 90th percentiles. 710 The reference value was set at the 10th percentile. Models were adjusted for age, sex, 711 race and ethnicity, education, BMI, eGFR, and NHANES cycle year. The histograms in 712 the background represent the distribution of each VOC metabolite (ng/mg creatinine). 713 See Figure S2 for DBP. 714











Figure 2. Prevalence ratios (PR) (95% confidence interval, CI) of hypertension by 718 urinary VOC levels (ng/mg creatinine) modeled as restricted quadratic splines among 719 nonsmoking NHANES 2011-2018 participants (n=4,430). Lines (shaded areas) 720 721 represent the PR (95%CI) of hypertension by VOC metabolites modeled as restricted quadratic splines for log transformed VOC metabolite distributions with knots at 10th. 722 50th, and 90th percentiles. The reference value was set at the 10th percentile. Models 723 were adjusted for age, sex, race and ethnicity, education, BMI, eGFR, and NHANES 724 cycle year. The histograms in the background represent the distribution of each VOC 725 metabolite (ng/mg creatinine). See Figure S2 for DBP. 726 727



